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Background: Olodaterol is a novel long-acting b2-agonist (LABA) with 24-h duration of action
in preclinical and clinical studies.
Objective: This Phase II, multicentre, randomised, double-blind, placebo-controlled, parallel-
group, dose-finding study evaluated four doses of once-daily olodaterol over 4 weeks in pa-
tients with chronic obstructive pulmonary disease (COPD), based on efficacy, safety and phar-
macokinetic parameters.
Methods: Patients received olodaterol inhalation solution or placebo via Respimat Soft Mist
inhaler once daily for 4 weeks. Pulmonary function testing was performed pre-dose (trough)
and up to 3 or 6 h post-dose, depending on visit. Primary end point was change from baseline
in trough forced expiratory volume in 1 s (FEV1) after 4 weeks’ treatment. Secondary end
points included change from baseline in peak FEV1 and FEV1 area under the curve from 0 to 6 h.UC0e6, area under the curve from 0 to 6 h; COPD, chronic obstructive pulmonary disease; Cmax,
expiratory volume in 1 s; FVC, forced vital capacity; gCV, geometric coefficient of variation; LABA,
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Phase II dose-finding study for olodaterol in COPD 597Results: 405 patients with COPD were randomised and assigned to treatment. Mean baseline
post-bronchodilator FEV1 was 1.50 L (54% predicted). All olodaterol doses provided statistically
significant increases in trough FEV1 compared to placebo (2 mg: 0.061 L [p Z 0.0233]; 5 mg:
0.097 L [p Z 0.0003]; 10 mg: 0.123 L [p < 0.0001]; 20 mg: 0.132 L [p < 0.0001]). A clear
doseeresponse relationship was demonstrated regarding pulmonary function; the two highest
olodaterol doses (10 and 20 mg) formed the plateau of the doseeresponse curve. All olodaterol
doses were well tolerated, with no dose-dependent safety effects.
Conclusion: Once-daily olodaterol demonstrated 24-h bronchodilator efficacy, confirming its
potential as a once-daily LABA for the management of COPD.
Trial registration: ClinicalTrials.gov: NCT00452400.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Figure 1 Study design.Introduction
Chronic obstructive pulmonary disease (COPD) is a signifi-
cant cause of morbidity, mortality and health-care costs,
with an estimated 65 million people worldwide experiencing
moderate to severe disease activity according to World
Health Organization estimates [1]. COPD is characterised by
persistent and progressive airflow limitation, and is associ-
ated with chronic and progressive dyspnoea, cough and
sputum production [2]. Treatment guidelines recommend
the use of long-acting bronchodilators, such as long-acting
b2-agonists (LABAs) and long-acting muscarinic antagonists,
for the maintenance treatment of patients with COPD when
symptoms are not adequately controlled with short-acting
agents [2]. The introduction of LABAs with a duration of
action ofw12 h, nearly two decades ago, provided patients
with superior bronchodilator efficacy and improved out-
comes compared to that of shorter-acting agents [3,4].
Recently, several LABAs with a duration of action of w24 h
have been developed, providing the potential for once-daily
pharmacotherapies that could offer improved treatment
adherence as well as the opportunity for combination with
other once-daily drugs such as tiotropium [5e8].
Olodaterol, which belongs to this new generation of
LABAs, is characterised by enantiomeric purity, a high b2-
receptor selectivity and a near full agonist response at the
human b2-adrenoceptor in vitro [9]. In preclinical animal
studies, olodaterol shows a rapid onset of action and in-
hibits acetylcholine-induced bronchospasms in anaes-
thetised guinea pigs and dogs [10]. Moreover, this
bronchoprotective effect was demonstrated to last >24 h in
both models [10].
This study is part of a series of trials designed to
establish the optimum dose and treatment regimen for
olodaterol in patients with COPD. An initial single-dose
study demonstrated effective bronchodilation over 24 h for
a range of olodaterol doses (2, 5, 10 and 20 mg) in a dose-
dependent manner [11].
The primary objectives of this Phase II study were,
therefore, to confirm the 24-h bronchodilator efficacy of
olodaterol after once-daily administration in patients with
COPD over an extended 4-week treatment period and to
determine the most appropriate dose for the Phase III
studies. The Phase III studies have now been performed and
demonstrated the efficacy and tolerability of olodaterol5 and 10 mg [12e15]. Additional objectives of this Phase II
study were to evaluate the safety and tolerability of olo-
daterol as well as systemic pharmacodynamic and phar-
macokinetic parameters.Methods
Patients
Patients were enrolled if they met the following inclusion
criteria: aged 40 years with a diagnosis of COPD [16];
current or ex-smokers with a smoking history of >10 pack-
years; a post-bronchodilator forced expiratory volume in 1 s
(FEV1) of 30% and <80% of predicted normal; and a post-
bronchodilator FEV1/forced vital capacity (FVC) <70%. Key
exclusion criteria were: a history of asthma; a history of
myocardial infarction (within 1 year); clinically relevant
cardiac arrhythmia; marked prolongation of QT/QTc inter-
val (QTc interval >450 ms); regular use of daytime oxygen
therapy; and use of b-adrenergic antagonists (b-blockers).
Study design
This was a Phase II, 4-week, multi-dose, multicentre,
multinational, randomised, double-blind, placebo-
controlled, parallel-group study registered with Clinical-
Trials.gov (NCT00452400). Following an initial screening
phase, patients entered a 2-week baseline period to ensure
clinical stability (Fig. 1).
598 M. Reza Maleki-Yazdi et al.Eligible patients were randomly assigned to 4 weeks of
double-blind treatment, in which they received an inhalation
solution containing one of four olodaterol doses (2, 5, 10 or
20 mg), or placebo, delivered by the Respimat Soft Mist
inhaler. Each administration of olodaterol comprised two
actuations from the Respimat device. Patients were evalu-
ated for an additional 30 days following completion of the
randomised treatment period. Patientswere permitted to use
inhaled corticosteroids, short-acting anticholinergics and low
doses of oral corticosteroids (equivalent to prednisone
10mg/day or 20mgprednisone every other day) if stabilised
for 6 weeks prior to screening. Concomitant use of methyl-
xanthines, long-acting anticholinergic drugs and LABAs (other
than the study drug) was not allowed. Salbutamol was pro-
vided for use as a rescue medication if required.
The study was performed in accordance with the
Declaration of Helsinki, International Conference on Har-
monisation Good Clinical Practice guidelines and local
regulatory requirements. Prior to study initiation, the pro-
tocol was approved by the ethics research board of the
respective institutions and signed consent was obtained
from all patients.Assessments
Spirometry
At screening, the qualifying pulmonary function test and
reversibility testing using salbutamol were conducted.
Spirometry (FEV1, FVC) was used to assess primary and
secondary end points and was performed according to
American Thoracic Society and European Respiratory Soci-
ety criteria using the VIASYS Healthcare MasterScope [17].
Pulmonary function tests were performed at 1 h and 10 min
pre-dose and at 30 min, 1, 2 and 3 h post-dose on Day 1
(first dose), Day 8, Day 15 and Day 29. Additionally, on Day
29, pulmonary function tests were performed at 4, 5 and 6 h
post-dose.
The primary end point was trough FEV1 response (L)
determined at the end of the 4-week treatment period (Day
29). Trough FEV1 was defined as the mean of two pre-dose
FEV1 values (1 h, 10 min) (i.e. FEV1 at the end of the
24-h dosing interval). Trough FEV1 response was defined as
the change from baseline FEV1, which was defined as the
mean of the FEV1 value 1 h prior and 10 min prior to inha-
lation of the first dose of randomised treatment. Secondary
end points included: peak FEV1 response; FEV1 area under
the curve from 0 to 6 h (AUC0e6) response (Day 29); trough
and peak FVC response; and FVC AUC0e6 response (Day 29).
The severity of COPD symptoms (wheezing, shortness of
breath, coughing and tightness of chest) was recorded in
electronic case report forms using the scale of 0 Z none,
1Zmild, 2Zmoderate, 3Z severe. Scores were based on
investigators’ assessment of patients’ condition in the week
prior to the clinic visit and were evaluated prior to the
assessment of pulmonary function.
Safety assessments
Adverse events (AEs) were monitored and recorded at each
patient visit. Safety measurements including vital signs
(blood pressure and pulse rate), 12-lead electrocardiogram
and clinical laboratory tests were conducted on all patientsat screening and each subsequent treatment visit. Plasma
potassium and creatinine phosphokinase were measured as
systemic pharmacodynamic parameters. Other observa-
tions included COPD symptom scores, Physician’s Global
Evaluation, use of concomitant therapies and the need for
test-day rescue medication (salbutamol).
Pharmacokinetic assessments
Plasma concentrations of olodaterol and known metabo-
lites were assessed on Days 1, 8, 15 and 29 using 9e10 mL of
blood taken from a forearm vein prior to and following drug
inhalation. Urine samples were collected prior to and
following drug administration on Days 1 and 29. Plasma and
urine olodaterol concentrations were validated by high-
performance liquid chromatography, coupled to tandem
mass spectrometry assays.
Statistical analysis
The planned sample size of 80 evaluable patients per group
provided 90% power to detect a difference of 0.12 L from
placebo at the 5% level of significance (two-sided) [18],
assuming a standard deviation for trough FEV1 of 0.229 L.
The full analysis set was defined as all patients who were
randomised, had received at least one dose of study
treatment and had a valid baseline measurement for at
least one end point. The primary and secondary end points
were analysed using analysis of covariance, which
compared the bronchodilator efficacy of the five treat-
ments, as determined by trough FEV1 response (L) after 4
weeks of randomised therapy. In this analysis, ‘baseline
trough FEV1’ was a linear covariate, ‘treatment’ was a fixed
effect and ‘centre’ was a random effect.
Pharmacokinetic analysis of the plasma/urine
concentration-time data was carried out by non-
compartmental analysis using the WinNonlin software
program (Professional, Version 5.2, Pharsight Corporation,
Mountain View, California, USA). All randomised patients
who received at least one dose of study medication were
included in the safety evaluation, which was analysed using
descriptive statistical methods.
Results
Patient population
The trial was conducted between 12 March 2007 and
14 January 2008. A total of 621 patients were enrolled at
42 centres in four countries: Canada, Germany, The
Netherlands and the USA. Of those patients, 405 were
randomised and treated (Fig. 2 and Table 1).
In total, 17 patients prematurely discontinued from the
trial, the majority due to AEs. The average screening post-
bronchodilator FEV1 was 1.50 L (54% predicted normal). In
general, baseline patient characteristics were comparable
across treatment groups (Table 2).
Efficacy
Lung function
All olodaterol doses were significantly superior to placebo
for the primary efficacy end point of trough FEV1 response
Figure 2 CONSORT diagram illustrating patient flow.
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0.061 L for 2 mg [pZ 0.0233], 0.097 L for 5 mg [pZ 0.0003],
0.123 L for 10 mg [p < 0.0001] and 0.132 L for 20 mg
[p < 0.0001]) (Table 2). A clear doseeresponse relationship
between 2, 5 and 10 mg olodaterol treatments was evident,
with a more modest increase seen with 20 mg olodaterol
compared to 10 mg at Week 4 (Table 2 and Fig. 3).
FEV1 trough responses confirmed the 24-h bronchodi-
lator activity. All olodaterol doses demonstrated a statis-
tically significant increase versus placebo (p < 0.002) in
FEV1 at all time points post-dose after the first dose and
after 1, 2 and 4 weeks of treatment (Fig. 3).
All doses of olodaterol were superior to placebo for peak
FEV1 and FEV1 AUC0e6 following 4 weeks of olodaterol
treatment (Table 2). The statistically significant improve-
ments (p < 0.001) in peak FEV1 compared to placebo were
observed after the first dose and were maintained over the
4-week treatment period. Overall, there was an indication
of increased efficacy with increasing dose for 2, 5 and 10 mg
over the treatment period, with no further increase in ef-
ficacy observed with 20 mg compared to 10 mg. All doses of
olodaterol were statistically superior to placebo for FVC
trough, peak and AUC0e6 with the exception of trough FVC
for olodaterol 2 mg (Fig. 4 and Table 3).
Increased efficacy with 5, 10 and 20 mg doses of oloda-
terol compared to 2 mg was observed but a clear dose-
ordering effect was less apparent. The FVC time profiles
following olodaterol administration followed a similar
pattern to the FEV1 data (Fig. 4). The differences frombaseline 3 h after the first olodaterol dose were similar to
those after 4 weeks of treatment. A dose-dependent effect
on FVC AUC0e6 was evident between 2, 5 and 10 mg oloda-
terol. A slight reduction in FVC AUC0e6 and peak FVC was
observed for 20 mg olodaterol compared to 10 mg, in line
with the plateau observed at these doses for FEV1.
COPD symptom scores
COPD symptom scores were generally around the “Mild”
level (score of 1) for coughing and shortness of breath, and
between “None” and “Mild” for tightness of chest and
wheezing. The results for shortness of breath and wheezing
showed small improvements with olodaterol compared to
placebo but the differences were generally not statistically
significant. Most groups demonstrated statistically signifi-
cant improvements in shortness of breath at Week 1 and
wheezing at Week 2 (p < 0.05). There was no significant
improvement in cough or tightness of chest over the course
of the trial.
Safety
All olodaterol doses were well tolerated with no apparent
dose-dependent AEs over the 4-week treatment course
(Table 4); the number of patients who experienced any AE
during the trial was balanced across treatment groups.
Nasopharyngitis was reported in one patient in the pla-
cebo group and a total of 14 patients in the olodaterol
groups. However, no dose-dependent effect was observed,
e.g. nasopharyngitis occurred in two patients in both the 2 mg
Table 1 Patient demographics and baseline characteristics.
Placebo Olodaterol
(n Z 79) 2 mg QD
(n Z 81)
5 mg QD
(n Z 80)
10 mg QD
(n Z 86)
20 mg QD
(n Z 79)
Sex, n (%)
Male 39 (49.4) 42 (51.9) 56 (70.0) 51 (59.3) 46 (58.2)
Female 40 (50.6) 39 (48.1) 24 (30.0) 35 (40.7) 33 (41.8)
Mean (SD) age, years 62.7 (9.7) 63.8 (8.6) 63.3 (9.5) 63.6 (7.9) 63.2 (9.0)
Smoking status, n (%)
Current smokers 41 (51.9) 40 (49.4) 34 (42.5) 46 (53.5) 41 (51.9)
Ex-smokers 38 (48.1) 41 (50.6) 46 (57.5) 40 (46.5) 38 (48.1)
Mean (SD) smoking, pack-years 50.0 (25.0) 46.0 (20.9) 49.0 (25.1) 43.6 (18.5) 47.6 (23.3)
Post-bronchodilator screeninga
Mean (SD) FEV1, L 1.45 (0.47) 1.49 (0.47) 1.55 (0.50) 1.54 (0.53) 1.48 (0.53)
Mean (SD) % predicted normal FEV1 53.9 (12.7) 55.2 (13.4) 52.8 (13.6) 55.0 (12.9) 54.0 (13.3)
Mean (SD) FVC, L 2.87 (0.86) 2.95 (0.88) 3.14 (0.96) 3.04 (0.99) 2.93 (0.94)
Mean (SD) FEV1/FVC, % 51.67 (11.65) 51.12 (9.93) 50.38 (10.90) 51.58 (10.19) 51.15 (10.62)
Mean (SD) FEV1 % change from
pre-bronchodilator
14.4 (14.0) 15.9 (12.0) 19.9 (16.5) 17.5 (12.7) 17.8 (15.8)
Pulmonary medications at baseline, n (%)
Short-acting anticholinergicb 17 (21.5) 27 (33.3) 20 (25.0) 19 (22.1) 20 (25.3)
Long-acting anticholinergicc 13 (16.5) 7 (8.6) 18 (22.5) 15 (17.4) 9 (11.4)
Short-acting b-adrenergicd 42 (53.2) 55 (67.9) 50 (62.5) 45 (52.3) 52 (65.8)
Long-acting b-adrenergice 27 (34.2) 38 (46.9) 35 (43.8) 35 (40.7) 34 (43.0)
Inhaled corticosteroidb 39 (49.4) 40 (49.4) 37 (46.3) 43 (50.0) 37 (46.8)
QD, once daily; SD, standard deviation.
a 10e15 min after 400 mg of salbutamol.
b Permitted to continue throughout trial.
c Not permitted during any part of the study.
d Permitted as rescue medication during study.
e Permitted during baseline and follow-up periods only.
600 M. Reza Maleki-Yazdi et al.and 20 mg dose groups. The majority of AEs were mild to
moderate in nature, with only a small number of serious AEs
reported during the trial (eight patients). Serious AEs were
COPD exacerbation (two patients) and fall, acute sigmoid
diverticulitis, upper respiratory tract infection, bronchitis,
pleural effusion, gastrointestinal bleeding, road traffic ac-
cident, hip fracture, humerus fracture and lung cancer in
one patient each, with no indication that they were related
to the administration of olodaterol. A small number of AEs
occurred with a frequency of >3%, the most common
included nasopharyngitis, upper respiratory tract infection,
bronchitis, headache, dyspnoea, cough and COPD exacer-
bations (Table 4). Therewere no fatal events associatedwith
this study. AEs leading to discontinuation were recorded in
nine patients and were palpitations, sinusitis, syncope,
vasovagal syncope, cough, hip fracture, fatigue, dyspnoea,
gastrointestinal bleeding and upper respiratory tract infec-
tion in one patient each, and COPD in two patients, none of
which were considered to be related to the study treatment.
No dose-dependent relationship was evident with the small
number of AEs leading to discontinuation.
Serum potassium levels for 2, 5 and 10 mg olodaterol
after the first dose were similar to placebo. In contrast,
there were small but statistically significant (p < 0.01) re-
ductions in serum potassium levels for 20 mg olodaterol
compared to placebo at both 1 and 3 h post-dose. After
4 weeks of treatment, there were no statistically significant
differences in serum potassium levels at any dose versusplacebo, although with 20 mg olodaterol at 1 h post-dose, a
near-significant effect was observed (p Z 0.068). A similar
pattern was observed for creatinine phosphokinase,
another marker of pharmacodynamic activity.
No dose-dependent changes in systolic and diastolic
blood pressure or pulse rate were observed in any dose
groups during treatment. Results from the 12-lead elec-
trocardiogram showed no dose-dependent effects of olo-
daterol administration on heart rate. Changes from
baseline for QT and QTcF showed no consistent pattern
across the dose groups.
Pharmacokinetics
Plasma concentrations of olodaterol and its metabolites
were mostly below the limit of quantification for olodaterol
2 mg. In the 5e20 mg olodaterol dose groups, olodaterol and
olodateroleglucuronide plasma maximum concentrations
(Cmax) were observed after w10 min and 3 h, respectively,
following single and repeated inhalation. Olodaterol plasma
concentrations declined rapidly and representedw37e56%
of Cmax at 6 h on Day 29 following inhalation of 10 and 20 mg
olodaterol. Renal excretion of olodaterol was low and varied
from 0.341% (geometric coefficient of variation [gCV] 182%)
to 0.510% (gCV 102%) of the dose on Day 1, and between
0.628% (gCV 118%) to 0.814% (gCV 102%) of the dose on
Day 29. Systemic exposure parameters of olodaterol, steady-
state Cmax and steady-state area under the curve from 0 to
1 h increased proportionally within the 5e20 mg dose range.
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The findings from this 4-week, multi-dose study provide
further evidence of the 24-h bronchodilator efficacy of
olodaterol and support once-daily administration in pa-
tients with moderate to severe COPD. Statistically supe-
rior improvements in peak FEV1, FEV1 AUC0e6 and trough
FEV1 responses were observed with all once-daily doses of
olodaterol compared to placebo, following 4 weeks of
treatment. Trough FEV1 response was selected as the
primary end point for this study, as this measure gives the
best indication of potential for 24-h bronchodilator ac-
tivity. Hence, the consistent trough FEV1 improvement
across all measured time points supports the potential for
once-daily dosing with olodaterol. The limited improve-
ments in symptom score may be a result of the small size
of the study, and relatively low sensitivity of the scoring
system.
These findings extend previous study results after
single-dose administration in patients with COPD and
those with asthma [11,19], by providing an integrated
overview of multiple efficacy measures (trough, peak and
AUC0e6) that can be interpreted to gain an overview of the
bronchodilatory effect of olodaterol. Similar findings have
been reported in Phase II studies of tiotropium in patients
with COPD, with comparable improvements in trough,
peak and average FEV1, and in trough:peak FEV1 ratios
[20,21], to those observed in the current olodaterol study.
Investigation of a range of doses allowed characteri-
sation of the olodaterol doseeresponse curve. A clear
doseeresponse relationship was observed with respect to
pulmonary function for the tested dose range (2e20 mg
olodaterol) after 4 weeks of olodaterol treatment and
improvements in FVC supported those observed for FEV1.
Importantly, the study identified where the slope and
plateau of the doseeresponse curve lie. Taking into ac-
count all the results from the pulmonary function pa-
rameters in this study, the efficacy of 10 and 20 mg
olodaterol were relatively similar, suggesting that both
doses represent a plateau in therapeutic effect. These
olodaterol doses showed a consistent increase in efficacy
compared to 2 mg, suggesting that 2 mg is on the steep
portion of the doseeresponse curve. However, limitations
do exist in terms of the precision of characterisation of the
doseeresponse curve because the study was powered to
identify an effect versus placebo and not to identify sta-
tistically significant differences between olodaterol doses.
For example, while there is a clear distinction between
the 2 mg dose and 10 or 20 mg doses, the positioning of the
5 mg dose with respect to 2 and 10 mg is less clear. Further
evaluation of the doseeresponse curve was warranted,
therefore, by incorporating 5 mg and 10 mg doses in Phase
III investigations.
The findings of this study regarding the olodaterol
doseeresponse curve are broadly similar to those
observed in another Phase II investigation of olodaterol
(1222.3; NCT01809262). However, in that study, the sep-
aration between the 10 mg and 20 mg doses was greater
than in the current investigation. This may be explained
by the differences in study design and patient inclusion
criteria. For example, 1222.3 was a single-dose, five-way
Figure 3 Adjusted mean FEV1 (L): individual time points from 0 to 3 h after first dose (Day 1) and 0e6 h after 4 weeks of
treatment (Day 29).
602 M. Reza Maleki-Yazdi et al.crossover study that required patients to meet reversibility
criteria, specifically a bronchodilator responsiveness of 12%
from baseline FEV1 45 min after inhalation of salbutamol. In
contrast, the current study did not use the results of
reversibility testing as an inclusion criterion.
The present study demonstrated acceptable short-term
safety and tolerability profiles for once-daily olodaterol
treatment over 4 weeks in patients with COPD. The
occurrence of AEs was low, with mostly mild to moderate
intensities, equally distributed across all treatment groups.
The known systemic pharmacodynamic effects of LABAs
assist in the selection of appropriate doses for analysis of
efficacy. The dose-selection process in the current study
comprised assessment of efficacy across a range of oloda-
terol doses, in parallel with investigation of systemic
pharmacodynamic parameters known to be sensitive to b2-
agonists. This allowed clear identification of the dose lying
on the steep portion of the doseeresponse curve for effi-
cacy, the position of the plateau of this curve and also the
identification of the threshold of systemic pharmacody-
namic activity. There was little evidence for systemic
pharmacodynamic activity at the doses studied, with the
exception of small reductions in serum potassium concen-
trations at 20 mg olodaterol. Based on these considerations
and the satisfactory safety and tolerability profiles
observed, doses of 5 and 10 mg olodaterol were selected forFigure 4 Adjusted mean FVC (L): individual time points from 0
(Day 29).Phase III clinical trials which demonstrated a 24-h bron-
chodilatory profile and satisfactory tolerability in patients
with moderate to very severe COPD [12e15]. Olodaterol has
been approved for use in COPD in several countries.
Non-adherence to medication represents a significant
barrier to optimal disease management in COPD [22].
Hence, uncomplicated medication regimens with a reduced
dosing frequency should improve adherence by making
treatment more convenient [23]. Currently, a number of
new longer-acting b2-adrenoceptor agonists, of which
indacaterol is the first approved (in the EU, USA and Can-
ada), are under clinical development with the objective of
achieving once-daily dosing.
The current investigation, in combination with study
1222.3, established an appropriate lowest efficacious dose
of olodaterol, and the 24-h bronchodilator efficacy
observed suggested that once-daily posology may be a
viable strategy. This could prove advantageous for patients
in the advanced stages of COPD for whom combination
therapy with once-daily long-acting anticholinergics is
indicated to maximise bronchodilation. However, the fact
that olodaterol demonstrates sufficient 24-h bronchodilator
efficacy does not necessarily define it as a once-daily
treatment. A further Phase II investigation, study 1222.26
(NCT00846768), was conducted to assess the efficacy of
both once- and twice-daily dosing regimens [24]; this,to 6 h after first dose (Day 1) and after 4 weeks of treatment
Table 3 Adjusted mean (standard error) FVC response (trough, peak, AUC0e6) after 4 weeks of treatment (Day 29).
Treatment Trough FVC Peak FVC FVC AUC0e6
Response vs placebo p value Response vs placebo p value Response vs placebo p value
Placebo 0.026 (0.040) 0.152 (0.046) 0.009 (0.044)
Olodaterol 2 mg QD 0.068 (0.040) 0.094 (0.051) 0.0695 0.440 (0.046) 0.288 (0.061) <0.0001 0.271 (0.043) 0.262 (0.057) <0.0001
Olodaterol 5 mg QD 0.136 (0.040) 0.162 (0.052) 0.0018 0.432 (0.046) 0.280 (0.062) <0.0001 0.292 (0.044) 0.283 (0.057) <0.0001
Olodaterol 10 mg QD 0.146 (0.039) 0.172 (0.051) 0.0008 0.449 (0.044) 0.297 (0.061) <0.0001 0.320 (0.042) 0.311 (0.056) <0.0001
Olodaterol 20 mg QD 0.153 (0.040) 0.179 (0.052) 0.0006 0.438 (0.046) 0.286 (0.062) <0.0001 0.313 (0.044) 0.304 (0.057) <0.0001
QD, once daily.
Table 4 Summary of AEs with an incidence of >3%.
Event Placebo, n (%) Olodaterol 2 mg QD, n (%) Olodaterol 5 mg QD, n (%) Olodaterol 10 mg QD, n (%) Olodaterol 20 mg QD, n (%)
Total treated 79 (100) 81 (100) 80 (100) 86 (100) 79 (100)
Total with any AE 29 (36.7) 30 (37.0) 33 (41.3) 26 (30.2) 30 (38.0)
Nasopharyngitis 1 (1.3) 2 (2.5) 6 (7.5) 4 (4.7) 2 (2.5)
Upper respiratory tract infection 1 (1.3) 0 (0.0) 2 (2.5) 1 (1.2) 4 (5.1)
Bronchitis 0 (0.0) 1 (1.2) 3 (3.8) 2 (2.3) 0 (0.0)
Headache 4 (5.1) 3 (3.7) 1 (1.3) 3 (3.5) 1 (1.3)
Dyspnoea 6 (7.6) 3 (3.7) 2 (2.5) 0 (0.0) 3 (3.8)
Cough 2 (2.5) 4 (4.9) 6 (7.5) 2 (2.3) 2 (2.5)
COPD exacerbation 2 (2.5) 3 (3.7) 2 (2.5) 4 (4.7) 2 (2.5)
QD, once daily.
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604 M. Reza Maleki-Yazdi et al.together with other olodaterol data, led to the develop-
ment of olodaterol as a once-daily agent.Conflicts of interest
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